Condition: Progressive Keratoconus · Sponsor: TBF Genie Tissulaire
Crosslinking is a therapeutic technique used to increase the rigidity of the cornea in order to slow or stop progression of keratoconus. The main complication of the treatment of keratoconus by crosslinking is postoperative pain due to the removal of the corneal epithelium. Currently, the management of pain is done through the administration of artificial tears and paracetamol. The amniotic membrane is a biological tissue used in ophthalmology to treat injuries of the surface of the eye. It has healing and analgesic properties. The objective of this multicenter randomized study is to evaluate the benefit of placing an amniotic membrane on the eye post-crosslinking to reduce pain and promote corneal healing.
This description comes directly from the study's public registry record.
Laurence BARNOUIN, MD · 0472686909 · laurence.barnouin@tbf-lab.com
Justine BOSC, MSc · 4 72 68 69 11 · justine.bosc@tbf-lab.com
Always discuss trial participation with your own doctor first.
| CHU de Brest | Brest, France | Recruiting |
| Hospices Civils de Lyon | Lyon, France | Recruiting |
| Assistance Publique - Hôpitaux de Marseille | Marseille, France | Recruiting |
| CHU de Montpellier | Montpellier, France | Recruiting |
| CHU de Nantes | Nantes, France | Not Yet Recruiting |
| Hôpital National de la Vision des Quinze-Vingts | Paris, France | Recruiting |
| CHU de Saint-Etienne | Saint-Priest-en-Jarez, France | Recruiting |
| Hôpitaux Universitaires de Strasbourg | Strasbourg, France | Recruiting |
| CHU de Toulouse | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06450470